Which of the following is NOT listed as secondary stroke prevention in the material?

• A. DAPT with Clopidogrel and Aspirin
• B. High intensity statin
• C. Anticoagulant
• D. Aspirin alone

Answer: (D)

Secondary stroke prevention focuses on reducing the chance of another stroke by addressing platelets, lipids, and potential cardiac sources of embolism. The material highlights three approaches: using dual antiplatelet therapy with clopidogrel and aspirin, employing a high-intensity statin, and applying anticoagulation when a cardioembolic source is present. The combination of aspirin with clopidogrel is used for short-term prevention after a minor stroke or high-risk TIA because it lowers early recurrence more effectively than aspirin alone, though bleeding risk limits long-term use. A high-intensity statin helps stabilize plaques and lower vascular risk, and anticoagulants are key when atrial fibrillation or other cardioembolic sources are identified. Aspirin alone, while a valid antiplatelet option in many settings, isn’t listed in this particular material’s secondary prevention lineup, likely because the emphasis is on the stronger or more specific regimens (short-term DAPT, statin, anticoagulation) rather than aspirin monotherapy.